PRA Health Sciences, a leading global contract research organization, today announced its new Predictivv™ platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development. The Predictivv™ platform will be a fully integrated solution for designing, planning and optimizing the management of global clinical studies. Designed around a unified platform that harmonizes data, processes, and people across every aspect of a clinical study, Predictivv™ will enable unprecedented adaptive intelligence and decision support for the ever-increasing complexities of the clinical development process.
“Predictivv™ is another step in PRA’s ambitious goal to change the future of clinical development,” said CEO Colin Shannon. “As we enter a new era of clinical development led by ideas like adaptive trial design and riskâbased monitoring, we recognized that existing clinical-trial management solutions did not support the realâtime modifications of protocols and operational plans required by adaptive models and the high risks associated with managing this complexity.”
The Predictivv™ platform will seamlessly bring together a series of clinical study applications representing the foundation of a true end-to-end clinical development process. Predictivv™ combines data input and continuous feedback from across the spectrum of the trial process, empowering decision support intelligence throughout the entire clinical lifecycle.
“One of the primary goals we established when designing the Predictivv platform was to provide the industry with unprecedented transparency into their portfolio of studies,” said Shannon. Through a proprietary analytics engine, Predictivv™ will not only provide transparency into all key processes and their statuses, but it will be capable of proactively identifying process and protocol deviations, enabling course corrections before risks occur.
Among the first applications that will be available in the PredictivvTM platform is Predictivv Connect™. Connect is a highly configurable solution that provides real time insights into every phase of clinical trial management, empowering clients and key stakeholders to connect and use data within their studies in an entirely new way.
With its investment in the Predictivv™ platform, PRA anticipates launching several new applications that focus on key aspects of clinical trial management, including areas such as site selection, patient recruitment and investigator engagement. PredictivvTM applications will be device independent, allowing users to explore data, uncover new insights and take action instantly from any device.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.